Drug Type Small molecule drug |
Synonyms SYHX-1901, SYHX1901 |
Target |
Action inhibitors |
Mechanism JAK inhibitors(Janus kinase inhibitors), Syk inhibitors(Spleen tyrosine kinase inhibitors), TYK2 inhibitors(Tyrosine-protein kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Nonsegmental vitiligo | Phase 3 | China | 06 Feb 2026 | |
| Plaque psoriasis | Phase 3 | China | 04 Jun 2025 | |
| Chronic large plaque psoriasis | Phase 3 | - | 01 Jun 2025 | |
| Alopecia Areata | Phase 3 | China | - | |
| Psoriasis | Phase 3 | China | - | |
| Vitiligo | Phase 3 | China | - | |
| COVID-19 | Phase 1 | China | 23 Nov 2022 | |
| Rheumatoid Arthritis | Phase 1 | China | 15 Jul 2022 | |
| Systemic Lupus Erythematosus | Phase 1 | China | 15 Jul 2022 | |
| Hematologic Neoplasms | IND Approval | China | 13 Jan 2025 |
J Am Acad Dermatol Manual | Phase 2 | 93 | hhbqwlivmu(bwssmjurfg) = tfltldyobf yihssjeqav (xsjlvduenf ) View more | Positive | 17 Dec 2025 | ||
hhbqwlivmu(bwssmjurfg) = jdpqdogrxw yihssjeqav (xsjlvduenf ) View more |





